Emerald Health Therapeutics Inc EMHTF

Great News!!

[cannhealth]

Emerald Health Therapeutics Files 17 Patent Applications Covering Defined Dose Cannabis Products Unique Emerald cannabinoid formulations and dosage forms focused on providing consumers precise and differentiated products based on protected intellectual property VICTORIA, British Columbia, October 16, 2018 Emerald Health Therapeutics, Inc. (Emerald) (TSXV:EMH; OTCQX:EMHTF) has filed 17 provisional US patent applications covering Emeralds unique Defined Dose cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emeralds intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use.The products provide more precise and consistent delivery, dosage, and formulations. Defined Dose cannabis products will, when made available to the public, provide consumers with products currently not available. The seventeen Defined Dose cannabis patent applications relate to: Inhaled dosage forms for smoking Inhaled dosage forms for vaping; and Capsule and edible formulations and dosage forms based on a novel understanding of cannabinoid molecular pathways and how they influence disease mechanisms. Certain of the Defined Dose cannabis products are eligible for launch in Canada under existing Canadian regulations. Others are expected to be eligible under anticipated regulatory changes in 2019. We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety enhanced through GMP-compliant production and enhanced product utility achieved through knowledge of science. Emeralds filing of these patent applications is an important step, said Chris Wagner, CEO of Emerald. Our expanding research and development effort is focused on internal facilities and staff as well as forming key relationships with other cannabis research experts, such as our recently announced agreement with VivaCell Biotechologies Espana. Emeralds intent is to be at the forefront of understanding the mechanism of action of the endocannabinoid system and developing proprietary products that enable both medical and adult-use consumers to achieve measured outcomes with well characterized, reliable products, said Avtar Dhillon MD, Executive Chairman of Emerald. Our aim is to produce a product pipeline of next-wave cannabis products that fit the better-defined needs and preferences of consumers as Canada and other countries that legalize medical and recreational cannabis use. Although cannabis is not presently federally legal in the United States for commercial purposes, it is still the most important 'first to file' jurisdiction for intellectual property generation and protection activity pertaining to cannabis and cannabinoids. The Patent Cooperation Treaty permits Emerald to file Canadian and international versions of these US patent applications in 152 member countries worldwide over the coming year.